×
About 2,783 results

ALLMedicine™ Pituitary Tumors Center

Research & Reviews  1,349 results

Exploiting D2R β-arrestin2-biased signaling to suppress tumor growth of pituitary adeno...
https://doi.org/10.1111/bph.15504
British Journal of Pharmacology; Tan Z, Lei Z et. al.

Apr 27th, 2021 - Dopamine agonists (DAs) targeting dopamine receptor D2 (D2R) have been used for decades in treating pituitary adenomas. There has been little clear evidence implicating the canonical G protein signaling as the mechanism by which D2R suppresses the...

Ki-67 labeling index and Knosp classification of pituitary adenomas.
https://doi.org/10.1080/02688697.2021.1884186
British Journal of Neurosurgery; Yuhan L, Zhiqun W et. al.

Apr 27th, 2021 - The classification of pituitary tumors is frequently updated to optimize guidance for clinical treatment based on current knowledge. To date, the World Health Organization conducts periodic expert review consensus meetings and publishes the result...

Novel Bendable Ring Curette for Endoscopic Transsphenoidal Surgery for Pituitary Tumors.
https://doi.org/10.1016/j.wneu.2021.04.027
World Neurosurgery; Kawamata T, Amano K

Apr 19th, 2021 - In transsphenoidal resection of pituitary tumors, even dedicated instruments sometimes cannot readily reach the surgical fields and they interfere with the endoscope and other instruments, making instrumental manipulations difficult and often inef...

Individuals with isolated congenital GH deficiency due to a GHRH receptor gene mutation...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050633
Endocrine Melo MA, Borges LP et. al.

Apr 16th, 2021 - Several interactions exist between the GH/IGF axis and the immune system, including effects on innate immunity and humoral and cellular response. Acquired GH deficiency (GHD) has been recently proposed as a risk factor for severity of COVID-19 inf...

Pituitary tumors and immortalized cell lines generated by cre-inducible expression of S...
https://doi.org/10.1210/endocr/bqab073
Endocrinology Daly AZ, Mortensen AH et. al.

Apr 10th, 2021 - Targeted oncogenesis is the process of driving tumor formation by engineering transgenic mice that express an oncogene under the control of a cell-type specific promoter. Such tumors can be adapted to cell culture, providing immortalized cell line...

see more →

Guidelines  3 results

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on th...
https://doi.org/10.1227/NEU.0000000000001386
Neurosurgery Aghi MK, Chen CC et. al.

Sep 16th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are the most frequent pituitary tumors. To create evidence-based guidelines for the initial management of NFPAs. A multidisciplinary task force composed of physician volunteers and evidence-based medicine-...

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Pre...
https://doi.org/10.1227/NEU.0000000000001388
Neurosurgery Newman SA, Turbin RE et. al.

Sep 16th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are the most frequent pituitary tumors. Visual symptoms from NFPAs are common and include visual field defects, loss of central vision, and motility problems resulting in diplopia. To create evidence-based...

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Pos...
https://doi.org/10.1227/NEU.0000000000001392
Neurosurgery Ziu M, Dunn IF et. al.

Sep 16th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are the most frequent pituitary tumors. Due to the lack of hormonal hypersecretion, posttreatment follow-up evaluation of NFPAs is challenging. To create evidence-based guidelines in an attempt to formulat...

see more →

Clinicaltrials.gov  1,391 results

Exploiting D2R β-arrestin2-biased signaling to suppress tumor growth of pituitary adeno...
https://doi.org/10.1111/bph.15504
British Journal of Pharmacology; Tan Z, Lei Z et. al.

Apr 27th, 2021 - Dopamine agonists (DAs) targeting dopamine receptor D2 (D2R) have been used for decades in treating pituitary adenomas. There has been little clear evidence implicating the canonical G protein signaling as the mechanism by which D2R suppresses the...

Ki-67 labeling index and Knosp classification of pituitary adenomas.
https://doi.org/10.1080/02688697.2021.1884186
British Journal of Neurosurgery; Yuhan L, Zhiqun W et. al.

Apr 27th, 2021 - The classification of pituitary tumors is frequently updated to optimize guidance for clinical treatment based on current knowledge. To date, the World Health Organization conducts periodic expert review consensus meetings and publishes the result...

Novel Bendable Ring Curette for Endoscopic Transsphenoidal Surgery for Pituitary Tumors.
https://doi.org/10.1016/j.wneu.2021.04.027
World Neurosurgery; Kawamata T, Amano K

Apr 19th, 2021 - In transsphenoidal resection of pituitary tumors, even dedicated instruments sometimes cannot readily reach the surgical fields and they interfere with the endoscope and other instruments, making instrumental manipulations difficult and often inef...

Individuals with isolated congenital GH deficiency due to a GHRH receptor gene mutation...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050633
Endocrine Melo MA, Borges LP et. al.

Apr 16th, 2021 - Several interactions exist between the GH/IGF axis and the immune system, including effects on innate immunity and humoral and cellular response. Acquired GH deficiency (GHD) has been recently proposed as a risk factor for severity of COVID-19 inf...

Pituitary tumors and immortalized cell lines generated by cre-inducible expression of S...
https://doi.org/10.1210/endocr/bqab073
Endocrinology Daly AZ, Mortensen AH et. al.

Apr 10th, 2021 - Targeted oncogenesis is the process of driving tumor formation by engineering transgenic mice that express an oncogene under the control of a cell-type specific promoter. Such tumors can be adapted to cell culture, providing immortalized cell line...

see more →

News  23 results

New Clinical Practice Guidelines, November 2017
https://reference.medscape.com/viewarticle/888107_10

Nov 7th, 2017 - Pituitary Tumors and Carcinomas European Society of Endocrinology Recommend all pituitary tumors undergo histopathologic analysis, which should include, at a minimum, immunodetection of pituitary hormones and Ki-67 proliferative index evaluation. ...

Temozolomide may help half of patients with aggressive pituitary tumors
https://www.mdedge.com/familymedicine/article/134819/endocrine-cancer/temozolomide-may-help-half-patients-aggressive
Clinical Endocrinology News; Michele G. Sullivan

Apr 2nd, 2017 - ORLANDO – Temozolomide, an alkylating agent approved for glioblastoma, improved long-term survival in about half of patients who took it for aggressive pituitary tumors, a retrospective study has determined. The study, conducted by members of the.

What Do You Consider to Be the Top Medical Advances of the Past 20 Years?
https://reference.medscape.com/viewarticle/845121_8

May 26th, 2015 - Which of the following would you say has been the biggest advance in endocrinology over the past 20 years? Your Peers Chose: The discovery of leptin 0% Introduction of tyrosine kinase inhibitors (TKIs) in the management of advanced thyroid cancers...

March 2015 Quiz 1
https://www.mdedge.com/gihepnews/article/97317/march-2015-quiz-1

Feb 20th, 2015 - ANSWER: D Critique The patient is most likely to have Zollinger-Ellison syndrome (ZES), a condition caused by a gastrinoma. In 25% of cases, ZES is associated with multiple endocrine neoplasia type 1 (MEN-1).

Pegvisomant Looks Safe for Long-Term Acromegaly Treatment
https://www.mdedge.com/internalmedicine/article/48806/endocrinology/pegvisomant-looks-safe-long-term-acromegaly-treatment
Jennie Smith

Mar 6th, 2012 - Interim results from an ongoing, registry-based phase IV surveillance study show that the medication pegvisomant is safe and effective in treating acromegaly, a disorder caused by pituitary tumors. Among 1,288 people treated for acromegaly with pe.

see more →

Patient Education  17 results see all →